-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The Management Committee of Shijiazhuang High-tech Industrial Development Zone Sends a Letter of Congratulations on Shijiazhuang Sihua Pharmaceutical Being Recognized as a National Quality Benchmark Enterprise
Category:
发布时间：2023-12-06
【概要描述】
On December 5, the Management Committee of Shijiazhuang High-tech Industrial Development Zone sent a letter of congratulations to Shijiazhuang Sihua Pharmaceutical Co., Ltd. on its recognition as a National Quality Benchmark Enterprise.
On December 5, the Management Committee of Shijiazhuang High-tech Industrial Development Zone sent a letter of congratulations to Shijiazhuang Sihua Pharmaceutical Co., Ltd. on its recognition as a National Quality Benchmark Enterprise.
In its congratulatory letter, the Management Committee of the Shijiazhuang High-tech Industrial Development Zone stated that Shijiazhuang Sihua Pharmaceutical Co., Ltd. has been recognized as a National Quality Benchmark Enterprise for 2023. The company’s submitted “21235 Risk Control Model Based on Parameter Release,” which demonstrates its proven practices in ensuring the quality and safety of pharmaceutical products, has been shortlisted as a model experience in the area of critical process quality control. This recognition is not only a distinguished honor for Shijiazhuang Sihua Pharmaceutical but also a source of great pride for the High-tech Zone. On the occasion of the company’s 75th anniversary, the Management Committee of the High-tech Zone extends its warmest congratulations to Shijiazhuang Sihua Pharmaceutical!
The congratulatory letter notes that Shijiazhuang Sihua Pharmaceutical, as a key pillar enterprise in the biopharmaceutical industry of the Shijiazhuang High-tech Industrial Development Zone, has long upheld the principle of putting the people and life first, taking it as its mission to research, develop, and manufacture high-quality “Made-in-China” medicines. The company has accelerated its transformation and upgrading, continuously expanding and strengthening the pharmaceutical industry. In recent years, in particular, Shijiazhuang Sihua Pharmaceutical has seized development opportunities, aligned its innovation chain with the industrial value chain, focused on emerging fields, built new competitive advantages, and actively promoted scientific and technological self-reliance and strength. As a result, the company has accumulated a robust portfolio of innovative achievements, ushering in a new phase of iterative product development across such areas as specialty and high-end complex generic drugs, innovative drugs, improved new drugs, active pharmaceutical ingredients, biologics, and pharmaceutical packaging materials. These efforts have made outstanding contributions to the economic and social development of the High-tech Zone, enabling the company to successfully join the ranks of nationally recognized enterprises—including National High-tech Enterprises, National Demonstration Enterprises for Technological Innovation, China’s Best Industrial Enterprise for Pharmaceutical R&D Product Lines, National Quality Benchmark Enterprises, and Outstanding Brands in China’s Chemical Pharmaceutical Preparations Exports—and to steadily climb higher in the ranking of China’s Top 100 Pharmaceutical Companies, reaching 56th place in 2022.
The congratulatory letter warmly encourages all employees of Shijiazhuang No. 4 Pharmaceutical to cherish even more the distinguished honors they have earned through tireless striving, to stand at a new starting point, to continue upholding fine traditions, to further innovate their development philosophy, business practices, and management models, to comprehensively enhance the company’s brand value, technological content, and management standards, to stride boldly toward higher goals, and to make new and greater contributions to high-quality economic and social development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091